Skip to content

Oxelidine fumarate is used for postoperative analgesia in patients with thoracoscopic lobectomy Efficacy and safety studies

Oxelidine fumarate is used for postoperative analgesia in patients with thoracoscopic lobectomy Efficacy and safety studies

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093815
Enrollment
Unknown
Registered
2024-12-12
Start date
2025-01-01
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative analgesia

Interventions

Oxelidine no background dose group (Group A):30 mg oxelidine + normal saline + (3 antiemetics such as granisetron 9 mg) ?100 ml. The first load dose was intravenous injection of 1.5 mg, followed by pa
Oxellidine background dose group (Group B):30 mg oxelidine + normal saline + (3 antiemetics such as granisetron 9 mg) ?100 ml. The first dose was 0.2-0.4 mg/kg oxelidine + (3 antiemetics such as grani
Sufentanil group (Group C):30 mg oxelidine + normal saline + (3 antiemetics such as granisetron 9 mg) ?100 ml. The first dose was 100 µg sufentanil + normal saline + (3 antiemetics such as granisetron

Sponsors

Zigong Fourth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients ranged in age from 18 to 65. No gender limitation; American Association of Anesthesiologists (ASA) Level I-III for Medical conditions; Patients undergoing thoracoscopic lobectomy.

Exclusion criteria

Exclusion criteria: Patients with obstructive sleep apnea hypopnea syndrome (OSAHS); Combined with allergic disease; Patients currently using or dependent on opioids; Patients with chronic pain (including patients with cancer pain before surgery); Patients with severe cardiopulmonary dysfunction; Severe heart, liver or kidney dysfunction; Specific type of surgery or disease state; Patients undergoing thoracotomy for various reasons; Patients with delayed extubation after operation; Patients who are participating in other studies; Mental disorder or speech communication disorder; Patients who refuse to sign informed consent.

Design outcomes

Primary

MeasureTime frame
The number of times of moderate to severe pain in the 24 hours after surgery (NS > 4 requiring pain relief assistance was defined as 1 episode of moderate to severe pain).;

Secondary

MeasureTime frame
NRS scores were obtained at 4 h, 24 h, and 72 h after surgery;PCA press times;Adverse reactions: nausea, vomiting, respiratory depression, drowsiness;First time out of bed after surgery;Time of first postoperative defecation;Patient satisfaction with analgesia;Hospital stays;Antiemetics and glucocorticoids are allowed when nausea and vomiting occur;

Countries

China

Contacts

Public ContactLu Bin

Zigong Fourth People's Hospital

binludoctor@126.com+86 139 9004 4633

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026